Andrea Castiglioni
Research Subjects
Andrea Castiglioni has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Ferraresi
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale “A. Avogadro”, Via Solaroli 17, 28100 Novara, Italy
2 shared publications - Chinmay Maheshwari
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale, Via P. Solaroli 17, 28100 Novara, Italy;Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA, Italy
2 shared publications - Ciro Isidoro
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale “A. Avogadro”, Via Solaroli 17, 28100 Novara, Italy
2 shared publications - Danny N. Dhanasekaran
Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA, USA
2 shared publications - Uthman Walusimbi
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale, via Solaroli 17, 28100 Novara, Italy, Italy
2 shared publications - Chiara Lualdi
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale, via Solaroli 17, 28100 Novara, Italy, Italy
1 shared publication
Latest Publications
- Open Access
- 12 February 2026
- Published by MDPI AG in Preprints.org
PTEN Dephosphorylates BECLIN-1 to Regulate Serum-Dependent Autophagy in Thyroid Cancer Cells
PTEN is a well-established tumor suppressor that plays a central role in the regulation of cell growth, metabolism, and survival. As a protein-lipid dual phosphatase, PTEN negatively regulates the PI3K/AKT signaling pathway, which in turn modulates autophagy, a conserved catabolic process that allows cells to degrade and recycle intracellular components, through the downstream effector mTORC1. While this represents the canonical mechanism by which PTEN influences autophagy, here we show that PTEN also regulates autophagy through an alternative, AKT-independent pathway. Specifically, through genetic manipulations of PTEN expression in thyroid cancer cells, we identify BECLIN-1 as a direct target of PTEN protein phosphatase activity. PTEN physically associates with BECLIN-1 under both basal and nutrient-deprived conditions, promoting its dephosphorylation at serine 295, thus relieving AKT inhibition resulting in autophagy activation. This regulatory event correlates with increased autophagic flux under starvation, as reflected by enhanced LC3 I to LC3 II conversion. Importantly, BECLIN-1 dephosphorylation is mediated by PTEN protein phosphatase activity and does not require its lipid phosphatase function. Furthermore, bioinformatic analyses reveal that high PTEN expression, together with enhanced autophagic activity (MAP1LC3B), is associated with improved clinical outcome in cancer patients. These findings uncover a direct, AKT-independent mechanism by which PTEN controls autophagy by modulating BECLIN-1 phosphorylation status. Together, our results provide novel insight into how PTEN coordinates cellular adaptation to metabolic stress and highlight an additional pathway through which PTEN regulates the autophagic machinery in cancer cells.
- 12 February 2026
- Published by MDPI AG in Preprints.org
Open AccessPTEN Dephosphorylates BECLIN-1 to Regulate Serum-Dependent Autophagy in Thyroid Cancer Cells
PTEN is a well-established tumor suppressor that plays a central role in the regulation of cell growth, metabolism, and survival. As a protein-lipid dual phosphatase, PTEN negatively regulates the PI3K/AKT signaling pathway, which in turn modulates autophagy, a conserved catabolic process that allows cells to degrade and recycle intracellular components, through the downstream effector mTORC1. While this represents the canonical mechanism by which PTEN influences autophagy, here we show that PTEN also regulates autophagy through an alternative, AKT-independent pathway. Specifically, through genetic manipulations of PTEN expression in thyroid cancer cells, we identify BECLIN-1 as a direct target of PTEN protein phosphatase activity. PTEN physically associates with BECLIN-1 under both basal and nutrient-deprived conditions, promoting its dephosphorylation at serine 295, thus relieving AKT inhibition resulting in autophagy activation. This regulatory event correlates with increased autophagic flux under starvation, as reflected by enhanced LC3 I to LC3 II conversion. Importantly, BECLIN-1 dephosphorylation is mediated by PTEN protein phosphatase activity and does not require its lipid phosphatase function. Furthermore, bioinformatic analyses reveal that high PTEN expression, together with enhanced autophagic activity (MAP1LC3B), is associated with improved clinical outcome in cancer patients. These findings uncover a direct, AKT-independent mechanism by which PTEN controls autophagy by modulating BECLIN-1 phosphorylation status. Together, our results provide novel insight into how PTEN coordinates cellular adaptation to metabolic stress and highlight an additional pathway through which PTEN regulates the autophagic machinery in cancer cells.
- Open Access
- 25 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9380
The Biological Role and Clinical Significance of BECLIN-1 in Cancer
BECLIN-1 is a multidomain protein that, through dynamic interaction with a variety of partners, controls autophagy and apoptosis, two processes dysregulated in cancer cells, thus playing a crucial role in cell fate. Although mutations in the BECN1 gene are rare in cancer, its frequent monoallelic deletion contributes to spontaneous cancer initiation by impairing autophagy, establishing it as a haploinsufficient tumor suppressor gene. The expression and activity of BECLIN-1 are further modulated by epigenetic mechanisms, alternative splicing, post-translational modifications, and alternative partner interactions. These layers of regulation critically affect the autophagy response, with an impact on cell proliferation, motility, and resistance to multiple stress stimuli. In this review article we outline the structural and functional properties of BECLIN-1 and discuss how its altered expression and protein–protein interactions can be harnessed for diagnostic and therapeutic purposes in cancer.
- 25 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9380
Open AccessThe Biological Role and Clinical Significance of BECLIN-1 in Cancer
BECLIN-1 is a multidomain protein that, through dynamic interaction with a variety of partners, controls autophagy and apoptosis, two processes dysregulated in cancer cells, thus playing a crucial role in cell fate. Although mutations in the BECN1 gene are rare in cancer, its frequent monoallelic deletion contributes to spontaneous cancer initiation by impairing autophagy, establishing it as a haploinsufficient tumor suppressor gene. The expression and activity of BECLIN-1 are further modulated by epigenetic mechanisms, alternative splicing, post-translational modifications, and alternative partner interactions. These layers of regulation critically affect the autophagy response, with an impact on cell proliferation, motility, and resistance to multiple stress stimuli. In this review article we outline the structural and functional properties of BECLIN-1 and discuss how its altered expression and protein–protein interactions can be harnessed for diagnostic and therapeutic purposes in cancer.